The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background/Aims: Patients with diabetes mellitus (DM) and tuberculosis (TB) have increased morbidity and a high risk of treatment failure or recurrence. It is important to manage both diseases simultaneously. Among anti-diabetic drugs, metformin inhibits intracellular growth of mycobacteria. Therefore, we examined the effects of metformin on TB treatment, especially in patients with DM. Methods: This retrospective cohort study included patients with culture-positive pulmonary TB diagnosed between 2011 and 2012. The primary study outcome was sputum culture conversion after 2 months of treatment. Results: Of 499 patients diagnosed with culture-positive pulmonary TB, 105 (21%) had DM at diagnosis. Among them, 62 (59.5%) were treated with metformin. Baseline characteristics, except for the presence of chronic renal disease, were not significantly different between the metformin and non-metformin groups. Metformin treatment had no significant effect on sputum culture conversion (p = 0.60) and recurrence within 1 year after TB treatment completion (p = 0.39). However, metformin improved the sputum culture conversion rate in patients with cavitary pulmonary TB, who have higher bacterial loads (odds ratio, 10.8; 95% confidence interval, 1.22 to 95.63). Conclusions: Among cavitary pulmonary TB patients with DM, metformin can be an effective adjunctive anti-TB agent to improve sputum culture conversion after 2 months of treatment.

Original languageEnglish
Pages (from-to)933-940
Number of pages8
JournalKorean Journal of Internal Medicine
Volume33
Issue number5
DOIs
StatePublished - Sep 2018

Fingerprint

Metformin
Diabetes Mellitus
Tuberculosis
Sputum
Pulmonary Tuberculosis
Therapeutics
Recurrence
Bacterial Load
Mycobacterium
Treatment Failure
Chronic Renal Insufficiency
Cohort Studies
Retrospective Studies
Odds Ratio
Outcome Assessment (Health Care)
Confidence Intervals
Morbidity
Growth
Pharmaceutical Preparations

Keywords

  • Diabetes mellitus
  • Metformin
  • Tuberculosis

Cite this

@article{51fd12ee2a384785a9b2be0a83f3400a,
title = "The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus",
abstract = "Background/Aims: Patients with diabetes mellitus (DM) and tuberculosis (TB) have increased morbidity and a high risk of treatment failure or recurrence. It is important to manage both diseases simultaneously. Among anti-diabetic drugs, metformin inhibits intracellular growth of mycobacteria. Therefore, we examined the effects of metformin on TB treatment, especially in patients with DM. Methods: This retrospective cohort study included patients with culture-positive pulmonary TB diagnosed between 2011 and 2012. The primary study outcome was sputum culture conversion after 2 months of treatment. Results: Of 499 patients diagnosed with culture-positive pulmonary TB, 105 (21{\%}) had DM at diagnosis. Among them, 62 (59.5{\%}) were treated with metformin. Baseline characteristics, except for the presence of chronic renal disease, were not significantly different between the metformin and non-metformin groups. Metformin treatment had no significant effect on sputum culture conversion (p = 0.60) and recurrence within 1 year after TB treatment completion (p = 0.39). However, metformin improved the sputum culture conversion rate in patients with cavitary pulmonary TB, who have higher bacterial loads (odds ratio, 10.8; 95{\%} confidence interval, 1.22 to 95.63). Conclusions: Among cavitary pulmonary TB patients with DM, metformin can be an effective adjunctive anti-TB agent to improve sputum culture conversion after 2 months of treatment.",
keywords = "Diabetes mellitus, Metformin, Tuberculosis",
author = "Lee, {Ye Jin} and Han, {Sung Koo} and Park, {Ju Hee} and Lee, {Jung Kyu} and Kim, {Deog Keom} and Chung, {Hee Soon} and Heo, {Eun Young}",
year = "2018",
month = "9",
doi = "10.3904/kjim.2017.249",
language = "English",
volume = "33",
pages = "933--940",
journal = "The Korean journal of internal medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "5",

}

TY - JOUR

T1 - The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus

AU - Lee, Ye Jin

AU - Han, Sung Koo

AU - Park, Ju Hee

AU - Lee, Jung Kyu

AU - Kim, Deog Keom

AU - Chung, Hee Soon

AU - Heo, Eun Young

PY - 2018/9

Y1 - 2018/9

N2 - Background/Aims: Patients with diabetes mellitus (DM) and tuberculosis (TB) have increased morbidity and a high risk of treatment failure or recurrence. It is important to manage both diseases simultaneously. Among anti-diabetic drugs, metformin inhibits intracellular growth of mycobacteria. Therefore, we examined the effects of metformin on TB treatment, especially in patients with DM. Methods: This retrospective cohort study included patients with culture-positive pulmonary TB diagnosed between 2011 and 2012. The primary study outcome was sputum culture conversion after 2 months of treatment. Results: Of 499 patients diagnosed with culture-positive pulmonary TB, 105 (21%) had DM at diagnosis. Among them, 62 (59.5%) were treated with metformin. Baseline characteristics, except for the presence of chronic renal disease, were not significantly different between the metformin and non-metformin groups. Metformin treatment had no significant effect on sputum culture conversion (p = 0.60) and recurrence within 1 year after TB treatment completion (p = 0.39). However, metformin improved the sputum culture conversion rate in patients with cavitary pulmonary TB, who have higher bacterial loads (odds ratio, 10.8; 95% confidence interval, 1.22 to 95.63). Conclusions: Among cavitary pulmonary TB patients with DM, metformin can be an effective adjunctive anti-TB agent to improve sputum culture conversion after 2 months of treatment.

AB - Background/Aims: Patients with diabetes mellitus (DM) and tuberculosis (TB) have increased morbidity and a high risk of treatment failure or recurrence. It is important to manage both diseases simultaneously. Among anti-diabetic drugs, metformin inhibits intracellular growth of mycobacteria. Therefore, we examined the effects of metformin on TB treatment, especially in patients with DM. Methods: This retrospective cohort study included patients with culture-positive pulmonary TB diagnosed between 2011 and 2012. The primary study outcome was sputum culture conversion after 2 months of treatment. Results: Of 499 patients diagnosed with culture-positive pulmonary TB, 105 (21%) had DM at diagnosis. Among them, 62 (59.5%) were treated with metformin. Baseline characteristics, except for the presence of chronic renal disease, were not significantly different between the metformin and non-metformin groups. Metformin treatment had no significant effect on sputum culture conversion (p = 0.60) and recurrence within 1 year after TB treatment completion (p = 0.39). However, metformin improved the sputum culture conversion rate in patients with cavitary pulmonary TB, who have higher bacterial loads (odds ratio, 10.8; 95% confidence interval, 1.22 to 95.63). Conclusions: Among cavitary pulmonary TB patients with DM, metformin can be an effective adjunctive anti-TB agent to improve sputum culture conversion after 2 months of treatment.

KW - Diabetes mellitus

KW - Metformin

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85049273220&partnerID=8YFLogxK

U2 - 10.3904/kjim.2017.249

DO - 10.3904/kjim.2017.249

M3 - Article

C2 - 29540054

AN - SCOPUS:85049273220

VL - 33

SP - 933

EP - 940

JO - The Korean journal of internal medicine

JF - The Korean journal of internal medicine

SN - 1226-3303

IS - 5

ER -